Ultragenyx Pharmaceutical Inc
RARE33.760USD
+0.235+0.70%
收盘 11/26, 16:00（美东）报价延迟15分钟
3.26B总市值
亏损市盈率 TTM
关于 Ultragenyx Pharmaceutical Inc 公司
Ultragenyx Pharmaceutical Inc. 是一家生物制药公司。该公司专注于识别、收购、开发和商业化用于治疗严重罕见和极罕见遗传病的新产品。其疗法和临床阶段产品线包括四类产品：生物制剂、小分子、AAV 基因治疗和核酸候选产品。该公司的四种获批候选产品包括用于治疗 X 连锁低磷血症 (XLH) 和肿瘤诱发性骨软化症 (TIO) 的 Crysvita (burosumab)、用于治疗粘多糖贮积症 VII (MPSVII) 或 Sly 综合征的 Mepsevii (vestronidase alfa)、用于治疗长链脂肪酸氧化障碍 (LC-FAOD) 的 Dojorvi (triheptanoin) 和用于治疗纯合家族性高胆固醇血症 (HoFH) 的 Evkeeza (evinacumab)。其临床候选产品包括DTX401、DTX301和UX701。DTX401用于治疗Ia型糖原累积病。
Ultragenyx Pharmaceutical Inc简介
公司代码RARE
公司名称Ultragenyx Pharmaceutical Inc
上市日期Jan 31, 2014
CEODr. Emil D. Kakkis, M.D., Ph.D.
员工数量1294
证券类型Ordinary Share
年结日Jan 31
公司地址60 Leveroni Ct
城市NOVATO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94949
电话14154838800
网址https://www.ultragenyx.com/
公司代码RARE
上市日期Jan 31, 2014
CEODr. Emil D. Kakkis, M.D., Ph.D.
Ultragenyx Pharmaceutical Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+46.74%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
7.75K
-50.61%
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Mr. Eric Olson
Mr. Eric Olson
Chief Business Officer, Executive Vice President
Chief Business Officer, Executive Vice President
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
业务USD
名称
营收
占比
Crysvita royalty revenue
85.68M
51.46%
Crysvita
34.73M
20.86%
Dojolvi
23.21M
13.94%
Evkeeza
14.57M
8.75%
Mepsevii
8.31M
4.99%
地区USD
名称
营收
占比
North America
102.93M
61.82%
Latin America
32.97M
19.80%
Europe
26.40M
15.86%
Japan
4.20M
2.52%
业务
地区
业务USD
名称
营收
占比
Crysvita royalty revenue
85.68M
51.46%
Crysvita
34.73M
20.86%
Dojolvi
23.21M
13.94%
Evkeeza
14.57M
8.75%
Mepsevii
8.31M
4.99%
股东统计
更新时间: 11月18日 周二
更新时间: 11月18日 周二
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.48%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
其他
72.46%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.48%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
其他
72.46%
股东类型
持股股东
占比
Investment Advisor
51.75%
Investment Advisor/Hedge Fund
31.58%
Hedge Fund
15.20%
Individual Investor
3.48%
Research Firm
2.31%
Sovereign Wealth Fund
1.02%
Private Equity
1.02%
Pension Fund
0.52%
Bank and Trust
0.40%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
640
97.34M
100.90%
-3.53M
2025Q2
635
97.48M
101.32%
-2.63M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
2023Q2
591
75.05M
105.07%
-3.13M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
10.19M
10.58%
+217.20K
+2.18%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.02M
5.21%
+106.89K
+2.18%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.27M
2.36%
+1.89M
+495.36%
Jun 30, 2025
Sands Capital Management, LLC
3.94M
4.09%
-220.08K
-5.29%
Jun 30, 2025
State Street Investment Management (US)
2.57M
2.67%
-46.25K
-1.77%
Jun 30, 2025
RTW Investments L.P.
1.71M
1.77%
--
--
Jun 30, 2025
JP Morgan Asset Management
2.60M
2.7%
+2.56M
+5502.04%
Jun 30, 2025
Baker Bros. Advisors LP
2.77M
2.88%
+1.20M
+75.92%
Jun 30, 2025
Kakkis (Emil D)
2.69M
2.79%
-31.78K
-1.17%
Mar 07, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Motley Fool Small-Cap Growth ETF
3.15%
Global X Genomics & Biotechnology ETF
2.87%
Franklin Genomic Advancements ETF
1.35%
Virtus LifeSci Biotech Products ETF
1.27%
SPDR S&P Biotech ETF
1.21%
WisdomTree BioRevolution Fund
0.88%
Touchstone Sands Capital US Select Growth ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Multi-Manager Large Growth ETF
0.55%
Goldman Sachs Future Health Care Equity ETF
0.5%
查看更多
Motley Fool Small-Cap Growth ETF
占比3.15%
Global X Genomics & Biotechnology ETF
占比2.87%
Franklin Genomic Advancements ETF
占比1.35%
Virtus LifeSci Biotech Products ETF
占比1.27%
SPDR S&P Biotech ETF
占比1.21%
WisdomTree BioRevolution Fund
占比0.88%
Touchstone Sands Capital US Select Growth ETF
占比0.8%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.63%
First Trust Multi-Manager Large Growth ETF
占比0.55%
Goldman Sachs Future Health Care Equity ETF
占比0.5%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Ultragenyx Pharmaceutical Inc的前五大股东是谁？
Ultragenyx Pharmaceutical Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：10.19M，占总股份比例：10.58%。
BlackRock Institutional Trust Company, N.A.持有股份：5.02M，占总股份比例：5.21%。
Fidelity Management & Research Company LLC持有股份：2.27M，占总股份比例：2.36%。
Sands Capital Management, LLC持有股份：3.94M，占总股份比例：4.09%。
State Street Investment Management (US)持有股份：2.57M，占总股份比例：2.67%。
The Vanguard Group, Inc.持有股份：10.19M，占总股份比例：10.58%。
BlackRock Institutional Trust Company, N.A.持有股份：5.02M，占总股份比例：5.21%。
Fidelity Management & Research Company LLC持有股份：2.27M，占总股份比例：2.36%。
Sands Capital Management, LLC持有股份：3.94M，占总股份比例：4.09%。
State Street Investment Management (US)持有股份：2.57M，占总股份比例：2.67%。
Ultragenyx Pharmaceutical Inc的前三大股东类型是什么？
Ultragenyx Pharmaceutical Inc 的前三大股东类型分别是：
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
有多少机构持有Ultragenyx Pharmaceutical Inc(RARE)的股份？
截至2025Q3，共有640家机构持有Ultragenyx Pharmaceutical Inc的股份，合计持有的股份价值约为97.34M，占公司总股份的100.90%。与2025Q2相比，机构持股有所增加，增幅为-0.43%。
哪个业务部门对Ultragenyx Pharmaceutical Inc的收入贡献最大？
在FY2025Q2，Crysvita royalty revenue业务部门对Ultragenyx Pharmaceutical Inc的收入贡献最大，创收85.68M，占总收入的51.46%。
